Zurit Levine - Compugen Vice President - Research and Discovery

CGEN Stock  ILA 736.20  10.20  1.40%   

President

Dr. Zurit Levine, Ph.D., is Vice President Research and Discovery of Compugen Ltd., since 2011. She joined Compugen in 1999 and has held several positions in Compugens Research Development department. In 2004, she was appointed Director of Therapeutic Selection Validation, which position she held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was appointed Vice President, Research and Discovery since 2011.
Age 55
Tenure 13 years
Professional MarksPh.D
Phone(972) 3 765 8555
Webwww.cgen.com
Levine holds a B.Sc. in Biology, an M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.

Compugen Management Efficiency

The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.85 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Compugen has a current ratio of 9.41, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Compugen until it has trouble settling it off, either with new capital or with free cash flow. So, Compugen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Compugen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Compugen to invest in growth at high rates of return. When we think about Compugen's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Hillit ShacharBioLine RX
N/A
Arnon AharonBioLine RX
N/A
Abi VainsteinHarasBioLine RX
41
Eyal EmmanuelEvogene
50
Ido DorEvogene
41
Mark KapelEvogene
46
Ella SoraniBioLine RX
55
Amos ShacharEvogene
38
Ofer GonenClal Biotechnology Industries
44
Moshe PhillipBioLine RX
62
Gil BenMenachemPurple Biotech
48
Julian AdamsClal Biotechnology Industries
62
Eran KosoverEvogene
39
Alin SelaBrownEvogene
46
Arnon HeymanEvogene
39
David MalekBioLine RX
39
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 68 people. Compugen (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 73 people.

Management Performance

Compugen Leadership Team

Elected by the shareholders, the Compugen's board of directors comprises two types of representatives: Compugen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Compugen. The board's role is to monitor Compugen's management team and ensure that shareholders' interests are well served. Compugen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Compugen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Joshua Shemer, Independent External Director
Rivka Schwartz, VP Discovery
Paul Sekhri, Chairman of the Board
Martin Gerstel, Chairman of the Board
Zurit Levine, Vice President - Research and Discovery
Ari Krashin, Chief Financial Officer
Anat CohenDayag, President, Chief Executive Officer, Director
Ruth Arnon, Independent Director
Yair Aharonowitz, Independent External Director
Eran Dor, Gen Sec
Oliver Froescheis, Sr Devel
Alberto Sessa, Chief Officer
Michal Preminger, Director
Henry MD, VP Officer
Dov Hershberg, Director
Arie Ovadia, Independent External Director
Eran Perry, Director
Sanford Zweifach, Director
Gilead Halevy, Director
Yvonne Naughton, Head Communications
Kinneret Savitsky, Director
Henry Adewoye, Chief Medical Officer
Dorit Amitay, VP HR
JeanPierre Bizzari, Director
John Hunter, VP of Antibody RandD and Site Head of Compugen USA Inc

Compugen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Compugen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Compugen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Compugen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Compugen will appreciate offsetting losses from the drop in the long position's value.

Moving against Compugen Stock

  0.78ARAD Arad Investment InduPairCorr
  0.56ISRS Isras InvestmentPairCorr
  0.41BLRX BioLine RXPairCorr
The ability to find closely correlated positions to Compugen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Compugen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Compugen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Compugen to buy it.
The correlation of Compugen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Compugen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Compugen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Compugen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Compugen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Compugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Compugen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Compugen Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Compugen Stock analysis

When running Compugen's price analysis, check to measure Compugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compugen is operating at the current time. Most of Compugen's value examination focuses on studying past and present price action to predict the probability of Compugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compugen's price. Additionally, you may evaluate how the addition of Compugen to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Please note, there is a significant difference between Compugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Compugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Compugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.